After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension

被引：0
|
作者：
Tamargo, Juan [1 ]
机构：
[1] Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Plaza Ramon y Cajal S-N, Madrid 28040, Spain
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2024年 / 10卷 / 05期
关键词：
D O I：
10.1093/ehjcvp/pvae035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：371 / 373
页数：3
相关论文
共 50 条
  • [41] The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
    Steriade, Alexandru
    Seferian, Andrei
    Jais, Xavier
    Savale, Laurent
    Jutant, Etienne-Marie
    Parent, Florence
    Sitbon, Olivier
    Humbert, Marc
    Simonneau, Gerald
    Montani, David
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2014, 8 (03) : 84 - 92
  • [42] Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
    Droste, Annette S.
    Rohde, David
    Voelkers, Mirko
    Filusch, Arthur
    Bruckner, Thomas
    Borst, Mathias M.
    Katus, Hugo A.
    Meyer, F. Joachim
    [J]. RESPIRATORY RESEARCH, 2009, 10
  • [43] Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis
    Yuan, Wenming
    Cheng, Genyang
    Li, Bin
    Li, Yansheng
    Lu, Shan
    Liu, Dong
    Xiao, Jing
    Zhao, Zhanzheng
    [J]. BLOOD PRESSURE, 2017, 26 (03) : 139 - 149
  • [44] 4-D Tomographic Radionuclide Ventriculography in the Assessment of the Endothelin-receptor Antagonist Treatment Effect on the Right Ventricle Performance in the Patients with Idiopathic Pulmonary Arterial Hypertension
    Samoylenko, L. E.
    Arkhipova, O. A.
    Danilov, N. M.
    Martynyuk, T. V.
    Sergienko, V. B.
    Chazova, I. E.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S384 - S384
  • [45] Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension
    Sidharta, Patricia N.
    Kraehenbuehl, Stephan
    Dingemanse, Jasper
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (03) : 437 - 449
  • [46] Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
    Belge, Catharina
    Delcroix, Marion
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [47] Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
    Steiner, M. Kathryn
    Preston, Ioana R.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (05) : 943 - 952
  • [48] Evolution of Patients with Pulmonary Arterial Hypertension Starting Macitentan After the Discontinuation of Other Endothelin-Receptor Antagonists: Results of a Retrospective Study
    Cadenas-Menendez, Sergio
    Alvarez Vega, Pablo
    Oterino Manzanas, Armando
    Alonso Lecue, Pilar
    Roig Figueroa, Vicente
    Bedate Diaz, Pedro
    Ortiz de Saracho, Juan
    Cifrian Martinez, Jose Manuel
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 481 - 487
  • [49] Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
    O'Callaghan, Dermot S.
    Savale, Laurent
    Yaici, Azzedine
    Natali, Delphine
    Jais, Xavier
    Parent, Florence
    Montani, David
    Humbert, Marc
    Simonneau, Gerald
    Sitbon, Olivier
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1585 - 1596
  • [50] Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
    Langleben, David
    [J]. CLINICS IN CHEST MEDICINE, 2007, 28 (01) : 117 - +
12345